Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mean change of best-corrected visual acuity (BCVA) from the baseline that was lower in GB-102 1mg than aflibercept arm.
Is graybug vision (graybug) stock a buy or sell?
Graybug Vision has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings. According to analysts' consensus price target of $5.75, Graybug Vision has a forecasted upside of 316.7% from its current price of $1.38.
How many shares of graybug vision are shorted?
As of December 31st, there was short interest totaling 115,600 shares, a decline of 33.4% from the December 15th total of 173,600 shares. Based on an average daily trading volume, of 160,900 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.9% of the shares of the stock are sold short. View Graybug Vision's Short Interest.
Who underwrote graybug vision's IPO?
SVB Leerink and Piper Sandler served as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers. What is Graybug Vision's stock symbol?
When is graybug vision's next quarterly earnings release?
Graybug Vision is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022. View our earnings forecast for Graybug Vision. How were Graybug Vision's earnings last quarter?
Is Graybug a good investment?
Graybug Vision has 269.02% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
Is Graybug vision a buy?
Graybug Vision has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
What does Graybug vision do?
THE GRAYBUG VISION We work relentlessly to save sight through transformative science, creating solutions to treat vision-threatening diseases, that improve quality of life and care for all involved.
Will Gray stock go up?
On average, analysts forecast that GRAY's EPS will be -$1.73 for 2022, with the lowest EPS forecast at -$1.97, and the highest EPS forecast at -$1.50. On average, analysts forecast that GRAY's EPS will be -$1.34 for 2023, with the lowest EPS forecast at -$1.66, and the highest EPS forecast at -$1.00.
Should you buy GTN stock?
Gray Television Inc finds support from accumulated volume at $18.92 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Our recommended stop-loss: We hold a negative evaluation for this stock.
What does GREY Stock mean?
Gray (or “grey”) market trading generally occurs when a stock that has been suspended from trades off the market, or when new securities are bought and sold before official trading begins.
How Is Graybug Vision's Cash Burn Changing Over Time?
With the cash burn rate up 3.9% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How much cash does Graybug Vision have?
As at September 2020, Graybug Vision had cash of US$95m and no debt. In the last year, its cash burn was US$33m. That means it had a cash runway of about 2.9 years as of September 2020. Arguably, that's a prudent and sensible length of runway to have.
What is the NASDAQ symbol for Graybug Vision?
Graybug Vision trades on the NASDAQ under the ticker symbol "GRAY ."
What is Graybug Vision?
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
What is the P/B ratio of Graybug Vision?
Graybug Vision has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Does Graybug Vision pay dividends?
Graybug Vision does not currently pay a dividend.
